A platform for quickly creating and testing antibodies
Platform for the High Throughput Generation and Validation of Affinity Reagents
This study is working on a new way to quickly create and test special proteins called antibodies that can help treat diseases, so patients can get better treatments faster and more effectively.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Abbratech, INC. NIH-funded |
| Lab location | 1 site (Branford, UNITED STATES) |
| Project ID | NIH-10769854 on NIH RePORTER |
What this research studies
This research focuses on developing a comprehensive platform that enables the rapid generation and validation of recombinant monoclonal antibodies (mAbs). It utilizes innovative technologies such as the pATHENA vector system for fast conversion of antibody clones into functional molecules, and the Epivolve method for isolating specific antibodies. The platform also incorporates yeast display for measuring binding affinities and includes automated processes for high-throughput production. Patients may benefit from improved antibody therapies that are developed more efficiently through this advanced methodology.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who may benefit from monoclonal antibody therapies for their medical conditions.
Not a fit: Patients who do not require monoclonal antibody treatments or have conditions unrelated to antibody therapies may not receive benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to faster and more effective antibody treatments for various diseases.
How similar studies have performed: Other research has shown success in developing antibody platforms, but this specific integration of technologies is relatively novel.
Where this research is happening
Branford, UNITED STATES
- Abbratech, INC. — Branford, United States (Active)
Researchers
- Principal investigator: Weiner, Michael P — Abbratech, INC.
- Study coordinator: Weiner, Michael P
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.